Skip to main content
OpenTrials
Completed

NCT Number: NCT06354049

Reiki Therapy to Improve Key Symptoms in Integrative Oncology Clinic (REIKI)

The purpose of this research is to investigate the delivery of Reiki to integrative oncology patients and assess its potential for improving cancer-related symptoms in this population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Cleveland, Ohio, 44106, United States

About this study

Reiki is a biofield therapy originating in Japan, in which a trained practitioner places their hands on or above the body of a receiver or themselves to generate a relaxation and healing response. Systematic reviews and meta-analyses report Reiki to be effective for improving psychological and physical health symptoms. With respect to adults with cancer, Reiki has been shown to improve participants' relaxation, pain, fatigue, sleep, anxiety, stress, and wellbeing/quality of life compared to care as usual. However, one study showed no improvement in comfort and wellbeing in those receiving Reiki compared to sham Reiki control, but those receiving Reiki reported improvements above usual care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 - 89.
  • Neoplasm diagnosis (i.e., ICD-10 C00 - D49) confirmed in electronic health record (EHR)/Caisis
  • Receiving care at a UH Connor Whole Health Integrative Oncology Clinic.
  • Reporting at least three ESAS symptoms ≥4/10 at baseline screening including fatigue and ≥2 other symptoms on the 9-item questionnaire.
  • Able to speak and understand English.
  • Has an email address, and access to a computer with internet and/or a mobile device with a functioning data plan

Exclusion criteria

  • Significant cognitive impairment that has not been corrected.
  • Significant visual impairment that has not been corrected.
  • Unable to provide informed consent.
  • Active psychosis.
  • Pregnancy.
  • Metastatic disease.
  • Reiki therapy within 3 months of study enrollment
  • Active immunotherapy, chemotherapy, or radiation treatment, or completed within 3 months before study start. Aromatase inhibitors and tamoxifen are exceptions.

Treatment and study plan

reiki

Other

Reiki, originating in Japan, is a biofield therapy where a skilled practitioner places their hands on or above the body of the recipient or themselves to induce relaxation and promote healing.

Primary outcomes

  1. Recruitment rate as measured by the percentage of participants enrolled

    Time frame: 8 weeks post enrollment

    Calculated by total number of participants enrolled/ total number of participants eligible and 90% is considered successful for the recruitment rate.

  2. Retention rate as measured by the number of participants retained until the final survey point

    Time frame: 8 weeks post enrollment

    Calculated by number of participants retained until the final survey time point / number of participants enrolled. 70% of participant retention until the final survey time point will be considered successful.

  3. Attendance rate as measured by number of sessions attended per 6 sessions

    Time frame: 8 weeks post enrollment

    Total number of sessions attended per 6 sessions. Attendance rate of >/= 70% will be considered successful

  4. Protocol adherence rate as measured by the number of participants treated in manner consistent with the intervention

    Time frame: 8 weeks post enrollment

    Number of participants treated in manner consistent with intervention/total number of participants enrolled

  5. Acceptability as measured by the patient mean of participant satisfaction survey

    Time frame: 8 weeks post enrollment

    As assessed by participants mean for the Participants' satisfaction survey with the Reiki sessions, measured on a scale from 0 (Not at all satisfied) to 10 (Completely satisfied)

  6. Data completeness rate

    Time frame: 8 weeks post enrollment

    Data completeness of >/= 90% is considered satisfactory

Secondary outcomes

  1. Patient-reported outcomes as measured by PROMIS-29(Patient-Reported Outcomes Measurement Information System) score

    Time frame: Baseline, 8 weeks

    Changes from baseline in Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Activities, Pain Interference all measured by T-score, a 11 point numerical rating scale, with higher scores representing more pain calculated from a 5 point Likert scale, with higher scores representing more of the concept being measured.

  2. Patient-reported outcomes as measured by ESAS(Edmonton Symptom Assessment System) scale

    Time frame: Upto 8 weeks

    The rate of intensity of common cancer symptoms, including pain, nausea, anxiety, fatigue, and well-being as measured using ESAS scale of 0 to 10 where, 0 is no pain to 10 as worst possible pain.

Sponsors and collaborators

Lead sponsor

Case Comprehensive Cancer Center

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 9, 2024
Registry last updated
Nov 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.